Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

476 - Anti-VEGF and integrin-linked kinase knockdown inhibit angiogenesis in vitro and suppress vascular tumor growth in vivo


17 Dec 2016


Poster lunch


Peace Mabeta


Annals of Oncology (2016) 27 (suppl_9): ix1-ix8. 10.1093/annonc/mdw573


P. Mabeta

Author affiliations

  • Physiology, University of Pretoria, 0110 - Pretoria/ZA


Abstract 476


Angiogenesis is the process by which new blood vessels are formed. It is also a key feature in the growth and progression of several cancers. Studies have identified vascular endothelial factor (VEGF) as an important regulator of angiogenesis in both the physiological and pathological settings. In the context of cancer, VEGF signalling was shown to be impaired in several neoplasms. This discovery led to the development of therapies against VEGF. While antiangiogenic VEGF-targeted therapy has resulted in increased cancer patient survival, the development of resistance has necessitated the discovery of alternative or complimentary therapeutic strategies. Integrin-linked kinase (ILK) is an effector of integrin-mediated cell adhesion. It is also involved in the regulation of the PI3k/Akt pathway.


The effects of ILK knockdown and anti-VEGF were evaluated on endothelial cell proliferation using BRdU-labeling, and on migration and invasion using the xcelligence system. The effects of the combination treatment on vascular tumour growth were studied in C57BL/6 mice inoculated with sEnd.2 cells. The secretion of VEGF, platelet derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) were measured employing ELISA.


ILK knockdown with siRNA and anti-VEGF treatment with DMH4 resulted in a more pronounced decrease in cell survival, proliferation and migration when compared to the individual treatments, even following VEGF induction. The combination treatment was also more potent in inhibiting angiogenesis in vitro. Western blot analysis revealed the suppression of Akt phosphorylation. Also, results revealed a decrease in the expression of HIF1-α and nitric oxide (NO), as well as a decrease in proangiogenic factors, namely, VEGF, PDGF and bFGF. In vivo, there was a significant reduction in tumor diameter in vascular tumor-bearing mice treated with Cpd 22, an inhibitor of ILK and DMH4 (n = 6 per group; P 


Therefore, the combination approach may be useful in the elaboration of antiangiogenic therapy in vascular tumors, further studies are warranted.

Legal entity responsible for the study

Peace Mabeta


National Research Foundation; University of Pretoria


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings